Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
Transparency Directive Voting Rights and Capital
AstraZeneca completes agreement with Recordati for Seloken in Europe
AstraZeneca completes divestment agreement with Grünenthal for migraine treatment Zomig
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development